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ABSTRACT
Introduction: Parenteral anticoagulants may improve
outcomes in patients with cancer by reducing risk of
venous thromboembolic disease and through a direct
antitumour effect. Study-level systematic reviews
indicate a reduction in venous thromboembolism and
provide moderate confidence that a small survival
benefit exists. It remains unclear if any patient
subgroups experience potential benefits.
Methods and analysis: First, we will perform a
comprehensive systematic search of MEDLINE,
EMBASE and The Cochrane Library, hand search
scientific conference abstracts and check clinical
trials registries for randomised control trials of
participants with solid cancers who are administered
parenteral anticoagulants. We anticipate identifying at
least 15 trials, exceeding 9000 participants. Second,
we will perform an individual participant data meta-
analysis to explore the magnitude of survival benefit
and address whether subgroups of patients are more
likely to benefit from parenteral anticoagulants. All
analyses will follow the intention-to-treat principle.
For our primary outcome, mortality, we will use
multivariable hierarchical models with patient-level
variables as fixed effects and a categorical trial
variable as a random effect. We will adjust analysis
for important prognostic characteristics. To
investigate whether intervention effects vary by
predefined subgroups of patients, we will test
interaction terms in the statistical model.
Furthermore, we will develop a risk-prediction model
for venous thromboembolism, with a focus on
control patients of randomised trials.
Ethics and dissemination: Aside from maintaining
participant anonymity, there are no major ethical
concerns. This will be the first individual participant
Strengths and limitations of this study
▪ In addition to our extensive search and robust ana-
lysis, the strength of our study relates to the possi-
bility of identifying patient-level effect modifiers and
exploring the survival benefit suggested by our
study level meta-analysis.
▪ This will be the first IPDMA to address the health
effects of heparin on patients with cancer and to
provide important background for decision makers
in this field. Our results will likely receive attention
in the next editions of several guidelines given the
participation of several investigators in guideline
development groups (eg, the American College of
Chest Physicians, Cancer Care Ontario, American
Society of Hematology, American Society of Clinical
Oncology and National Comprehensive Cancer
Network).
▪ A number of knowledge users will be directly
involved in the project on various occasions. They
will take ownership through the involvement with
all stages of the project and coauthoring of
the publications resulting from this knowledge
synthesis.
▪ The American Hematological Society guideline
panel has already been involved in the generation of
the questions to be answered by this synthesis. We
believe that this offers an outstanding opportunity
for dissemination.
▪ The guideline developers will use the results of this
synthesis to inform their guideline recommenda-
tions and practice. Several of the knowledge users
will disseminate the results through presentations at
clinical rounds as well as national and international
conferences.
▪ Weaknesses of our study are in the risk of not obtain-
ing data from all studies that will be identified.
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data meta-analysis addressing heparin use among patients with
cancer and will directly influence recommendations in clinical
practice guidelines. Major cancer guideline development
organisations will use eventual results to inform their guideline
recommendations. Several knowledge users will disseminate
results through presentations at clinical rounds as well as national
and international conferences. We will prepare an evidence brief
and facilitate dialogue to engage policymakers and stakeholders in
acting on findings.
Trial registration number: PROSPERO CRD42013003526.
INTRODUCTION
Cancer is a leading cause of death worldwide. In
Canada, approximately 145 000 new cases are diagnosed
annually.1 The risk of venous thromboembolic complica-
tions is elevated in patients with cancer.2 3 The annual
risk of suffering a venous thromboembolic event (VTE),
estimated from control groups of randomised trials in
patients with solid cancer, is 4–5%.4 Patients who experi-
ence VTE frequently require hospital admission and/or
prolonged anticoagulant therapy. VTE is also associated
with impairments in function of day-to-day life and pain,
in addition to increased costs.5
Heparin and other LMWHs, such as fondaparinux and
danaparoid, do not have intrinsic anticoagulant activity
but potentiate antithrombin III, which inhibits activated
coagulation agents. These agents constitute indirect antic-
oagulants as their activity is mediated by plasma cofactors.6
Heparin and its low-molecular weight derivatives are not
absorbed orally and must be administered parenterally by
intravenous infusion or subcutaneous injections.7
Researchers have hypothesised that heparin may improve
outcomes in patients with cancer through an antitumour
effect in addition to its antithrombotic effect.8 This antitu-
mour activity of heparin, mechanistically, includes the
inhibition of cell–cell interaction by blocking cell-adhesion
molecules (selectins), the inhibition of extracellular-
matrix protease heparanase and the inhibition of angio-
genesis.9 In a 1992 clinical trial comparing nadroparin, a
LMWH, to unfractionated heparin (UFH) in patients with
proven deep venous thrombosis (DVT), nadroparin unex-
pectedly reduced mortality in the subgroup of patients
with cancer.10 However, anticoagulants may increase the
risk for bleeding and is likely higher in patients with
cancer. Heparins are also known to cause heparin-induced
thrombocytopaenia.11
We recently updated our study-level systematic review
evaluating the role of parenteral anticoagulants in
patients with cancer who have no other indication for
anticoagulant therapy.4 12 We identified a number of ran-
domised trials that, in the most recent iteration of our
update, suggested a survival benefit and a large reduction
in VTE. The results of the systematic review were used by
the American College of Chest Physicians (ACCP) antith-
rombotic guideline panel in its ninth iteration of the
guidelines.2 However, the members of this highly
influential guideline panel made a conditional recom-
mendation against the use of heparin because they were
uncertain as to whether or not the intervention reduced
mortality. Since then, new trials have been published and
we have updated our study-level systematic review (see
table 1 for the summary of findings table and online
supplementary appendix 1 for the detailed evidence
profile).
There are several key questions that remain
unanswered by this study-level meta-analysis. First, the
analysis of mortality remains inconclusive (the CI for the
relative risk included the value of 1.0), but survival ana-
lysis suggested a statistically significant mortality benefit.
Unfortunately, this cannot be further investigated
without IPD. Second, given the broad inclusion criteria
in the randomised controlled trials (RCTs), it is unclear
whether the effects are restricted to subgroups of
patients defined by the type (ie, primary tumour site) or
stage of cancer (eg, local vs metastatic).13 Third, there is
uncertainty about the appropriate duration of treatment
and whether or not there is an interaction with the
administration of chemotherapy and hormone therapy
(ie, the coadministration of chemotherapy or hormone
therapy may potentiate the beneficial effects of paren-
teral anticoagulants). Fourth, there is uncertainty
whether heparin has a direct antitumour effect. IPDMA
might be able to shed more light on this issue if survival
is prolonged independently of the occurrence of VTE.
Fifth, the baseline risk for VTEs and the risk of bleeding
are unknown in many of these patients and it is possible
that patient data from these trials can be used to
develop risk-prediction models.
To develop the best recommendations for patient care
and to make socially responsible decisions, guideline
panels and others developing recommendations must be
informed by the best possible summary of the evidence.
Study-level meta-analysis does not allow for the evalu-
ation of modifying factors and for survival analysis based
on prognostic factors of individual patients. An IPDMA
can help resolve these issues.
The results of this synthesis will directly inform the
recommendations of the next update of several clinical
practice guidelines that in turn will benefit clinicians
and patients with cancer. Furthermore, the results of this
project will inform decisions about the allocation of
healthcare resources.
OBJECTIVES
The primary objective of this IPDMA of RCTs is to assess
patient-important benefits and patient-important harms
of parenteral anticoagulants in patients with cancer who
have no other indication for anticoagulation. The use of
IPD will allow us to place greater confidence on effect
estimates and identify specific subgroups that are more
likely to benefit.
We will focus on the following unanswered clinical
questions:
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1. What is the impact on survival of parenteral anticoa-
gulants administered to patients with cancer with no
therapeutic or prophylactic indication for
anticoagulation?
2. Which subgroups of patients with cancer are more
likely to benefit than be harmed from
anticoagulation?
3. If there is a survival benefit from the use of paren-
teral anticoagulation in patients with cancer, is this
survival benefit a result of an antitumour effect?
Secondary objectives include seeking answers to the fol-
lowing questions:
1. Can biomarkers such as C reactive protein, D-dimers
and P-selectin be used to monitor or diagnose disease?
2. Can risk-prediction models to foresee the occurrence
of VTE be developed from patient data of included
trials?
3. What is the performance of the Khorana score and
extended Khorana score for predicting VTE?
METHODS/DESIGNS
This systematic review will be conducted according to
standards of the Cochrane Collaboration.14 Our proto-
col is currently registered in the International
Prospective Register for Systematic Reviews
(PROSPERO), CRD42013003526. Our systematic review
will adhere to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines for reporting systematic reviews.15
Inclusion/exclusion criteria
1. Types of studies: we will consider RCTs that provide
IPD.
2. Types of participants: patients with solid cancers with
no indication for prophylactic anticoagulation (eg,
for acute illness, for central venous line placement,
perioperative) or for therapeutic anticoagulation (eg,
for the treatment of DVT or PE). These are typically
patients with solid cancers undergoing chemotherapy
and/or radiotherapy in the outpatient setting.
3. Types of intervention:
▸ Experimental intervention—parenteral anticoa-
gulants such as UHF, LMWH and fondaparinux.
▸ Comparator intervention—placebo or no
intervention.
▸ We will also consider studies comparing differ-
ent parenteral anticoagulants. The protocol
should have planned to provide all other coin-
terventions (eg, chemotherapy) similarly.
Literature search
We will update our 2011 search of the following elec-
tronic bibliographic databases:12 MEDLINE, EMBASE,
The Cochrane Library (including Cochrane Central
Register of Controlled Trials/CENTRAL, Clinical Trials,
DARE and NHS EED). A professional librarian in collab-
oration with content, clinical and methodology experts
will develop specific search strategies. There will be
neither date nor language restrictions. We will also
review references of identified studies and narrative
review articles, and update our search of conference pro-
ceedings (conference proceedings of the American
Society of Clinical Oncology and of the American
Society of Hematology). We will also use the related
article feature in PubMed to identify additional articles.
Study selection
The inclusion criteria for this review are identical to our
previous study-level systematic review. We will attempt to
obtain IPD for RCTs that were previously analysed12 and
any new RCTs that we identify to be eligible. An overview
of known RCT’s we hope to include in eventual analysis
is provided in table 2.
For the study selection process, two reviewers will inde-
pendently assess titles and abstracts of all identified cita-
tions for potential eligibility based on predefined
criteria mentioned above. We will retrieve the full-text
Table 1 Summary of findings for study-level meta-analysis of parenteral anticoagulants in cancer
Estimated absolute effects at 1 year
Outcome†
Relative effect
(95% CI)
Without
LMWH
(per 1000)
With LMWH
(per 1000)
Difference
(per 1000)
Certainty of
the effect
Death RR 0.94 (0.88 to 1.00) 501 471 30 fewer deaths
(60 to 0 fewer)
⊕⊕○
Moderate due to
imprecision
Symptomatic venous
thromboembolism
RR 0.57 (0.40 to 0.81) 46 26 20 fewer events
(9 to 27 fewer)
⊕⊕⊕⊕
High
Major bleeding RR 1.06 (0.71 to 1.57) 16 17 1 more major bleed (from 5
fewer to 9 more)
⊕⊕⊕○
Moderate due to
imprecision
Minor bleeding RR 1.18 (0.89 to 1.55) 27 32 5 more minor bleeds (from
3 fewer to 15 more)
⊕⊕⊕⊕
High
CVC, central venous catheter; LMWH, low-molecular weight heparin; PE, pulmonary embolism.
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Table 2 Overview of identified trials fulfilling the eligibility criteria
Author year Trial name Type of cancer Anticoagulant
Number of
patients
randomised Outcomes
Agnelli 201216 Evaluation of Semuloparin sodium (AVE5026) in
the Prevention of venous thromboembolism in
patients with cancer undergoing chemotherapy
(SAVE-ONCO)
Patients with metastatic
or locally advanced
solid tumours
Semuloparin 3172 ▸ Survival (12 months)
▸ VTE
▸ Major bleeding, minor bleeding
Agnelli 200917 PROphylaxis of ThromboEmbolism during
CHemoTherapy (PROTECHT)
Metastatic or locally
advanced solid cancer
receiving chemotherapy
Nadroparin 1150 ▸ Survival (4–12 months)
▸ Response to chemo (4 months)
▸ Thrombotic complications in patients
with CVC
▸ Superficial thrombophlebitis of lower
limbs
▸ Asymptomatic thromboembolic
events
▸ Safety (bleeding, major, minor,
others, 4 months)
Altinbas
200418
A randomised clinical trial of combination
chemotherapy with and without
low-molecular-weight heparin in small cell lung
cancer
SCLC Dalteparin 84 ▸ All-cause mortality (12–24 months)
▸ Symptomatic DVT
▸ Bleeding
Haas 200519 Low-molecular-weight heparin versus
Placebo for the prevention of venous
Thromboembolism in metastatic
breast cancer or stage III/IV lung cancer (TOPIC 1
and 2)
Metastatic breast or
lung
Certoparin 900 ▸ Survival (6 months)
▸ Major and minor bleeding
▸ Venous thromboembolism
▸ Symptomatic and asymptomatic DVT
▸ PE—Vena subclavia, vena jugularis
▸ Superficial thrombophlebitis
▸ Symptomatic venous
thromboembolism
▸ Any thrombotic event
▸ Skeletal events
Kakkar 200420 The Fragmin Advanced Malignancy Outcome
Study (FAMOUS)
Advanced cancer Dalteparin 374 ▸ Mortality (12–24–36 months)
▸ Symptomatic venous
thromboembolism
▸ (PE, DVT)
▸ Major bleeding
▸ Minor bleeding
Klerk 200521 Malignancy and Low Molecular Weight Heparin
Therapy (MALT)
Advanced cancer Nadroparin 302 ▸ Mortality (6–12–24 months)
▸ Major bleeding
▸ Clinically relevant non-major
bleeding
▸ All clinically relevant bleeding (major
and non-major combined)
Continued
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Table 2 Continued
Author year Trial name Type of cancer Anticoagulant
Number of
patients
randomised Outcomes
Lebeau 199422 Subcutaneous heparin treatment
Increases survival in small cell
Lung cancer
SCLC Unfractionated
heparin
277 ▸ Survival (12–24–36 months)
▸ Bleeding
Lecumberri
201023
Adjuvant BEmiparin in small cell Lung carcinoma
(ABEL)
SCLC Bemiparin 26 ▸ Mortality (18 months)
▸ Bleeding
▸ Tumour progression
Maraveyas
201124
A phase II randomised study of
chemoanticoagulation (gemcitabine-dalteparin) vs
chemotherapy alone (gemcitabine) for locally
advanced and metastatic pancreatic
adenocarcinoma (FRAGEM)
Pancreatic cancer Dalteparin 123 ▸ VTE
▸ Survival
▸ Toxicity
▸ Time to disease progression
▸ Serological markers of
thromboangiogenisis
Macbeth25 A randomised phase III clinical trial investigating
the effect of FRAGMin added to standard therapy
in patients with lung cancer (FRAGMATIC)
Lung cancer Dalteparin 2202 ▸ Survival
▸ Serious adverse events
▸ Toxicity
▸ Quality of life
▸ Cost-effectiveness
Pelzer et al
200826
A prospective, randomised trial of simultaneous
pancreatic cancer treatment with enoxaparin and
ChemoTherapy (PROSPECT)
Advanced pancreatic
cancer on
chemotherapy
Enoxaparin 312 ▸ Overall survival
▸ Symptomatic VTE
▸ Major bleeding
▸ Time to progression
Perry 201027 A trial of dalteparin low molecular weight heparin
for primary prophylaxis of venous
thromboembolism in brain tumour patients
(PRODIGE)
Malignant glioma Dalterparin 186 ▸ Primary outcomes: symptomatic
DVT or PE.
▸ Secondary outcomes bleeding
(major and all bleeding)
▸ Quality of life
▸ Cognition assessments
▸ Death
Sideras
200628
Low-molecular-weight heparin in patients with
advanced cancer: a phase 3 clinical trial
Advanced cancer Dalteparin 137 ▸ Mortality (12 and 24 months)
▸ Symptomatic VTE
▸ Major/minor bleeding
Van Doormaal
201129
Improving with nadroparin the Prognosis in
advanced cancer treatment (INPACT)
NSCLC
Prostate cancer
Pancreatic cancer
Nadroparin 503 ▸ Mortality
▸ Disease progression
▸ Major/minor bleeding
▸ Venous thromboembolism (PE, DVT)
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articles of all citations deemed eligible by at least one
reviewer. Two reviewers will then screen the full texts for
eligibility using a standardised pilot tested form with
explicit inclusion and exclusion criteria. Decisions will
be compared and agreement will be measured using the
κ statistic.31 Disagreements will be resolved by consensus
and, when needed, with the help of a third reviewer. We
will record reasons for exclusion.
We will contact authors of all included trials by email,
fax or telephone, and invite them to share their data.
Specifically, we will request the study protocol, a copy of
the case report forms and the corresponding dataset
with all patient identifiers (eg, names) removed. In add-
ition to the study protocol and complete analysis plans,
a detailed list of all variables of interest will be provided
to contacted trialists in order to maintain analytical
transparency, to avoid data driven analysis and to
encourage apprehensive authors to share relevant trial
data, excluding sensitive or unnecessary information
from being disseminated. Data should include important
demographic variables that are required for the analysis
and, if possible, biomarker information.
Assessment of risk of bias and overall quality of evidence
Two review authors will assess, in duplicate and inde-
pendently, the risk of bias in the included trials, using a
standardised form. They will compare their results and
resolve disagreements by discussion or with the help of
a third reviewer. We will use the following criteria to
assess the risk of bias: Allocation concealment; blinding
of participants, healthcare providers, data collectors,
outcome adjudicators, and data analysts; proportion of
participants with available data; and stopping early for
benefit. We will assess selective outcome and other
reporting bias by comparing the list of outcomes in
published protocols and in the methods section to the
outcomes reported in the published paper. We will
assess the risk of bias and overall quality of evidence in
the study-level meta-analysis as an initial approach. We
will generate an inverted funnel plot for each compari-
son to check for possible publication bias. We will assess
statistical heterogeneity by calculating the Q χ2 and its
p value, and the I2. We will record and report the spon-
sorship of the studies (whether sponsored by a for-
profit or not-for-profit organisation or government
agency), and assess financial and intellectual conflicts
of interest.
We will prepare GRADE evidence profiles to summar-
ise the information about the treatment effects following
the GRADE approach17 to provide support for decision
makers, using our GRADE profiler software.18 For this
purpose, we will expand the existing GRADE methodo-
logical framework to incorporate assessing the quality of
evidence coming from IPDMA. For that, we will assess
publication bias and heterogeneity by using study-level
identifiers. We will conduct this assessment for the rela-
tive estimates of effect as well as baseline risk estimates
in various patient subgroups.
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Datasets and data extraction
The primary purpose of the project is to conduct an
IPDMA; if any investigators are unable or unwilling to
provide us with their database we will compare, in a sec-
ondary analysis, the results using study-level data, in
order to include all trials. We will request trial protocols,
final trial reports and unedited databases including all
randomised patients. Two review authors will independ-
ently extract individual participant data and aggregate
level data in duplicate using standardised prepiloted
data extraction forms. They will compare their results
and resolve disagreements by discussion or with the help
of a third reviewer. Data of interest include demo-
graphic, intervention and outcome data.
Trialists will be assured that their data will be treated
confidentially. All data sets received will be stored in a
secure location in their original formats. Prior to data
extraction, we will create a list of baseline variables (eg,
age, sex, date of cancer diagnosis, site of primary
cancer) and outcome variables (eg, mortality, bleeding,
DVT, PE) to be used in the IPDMA. We will then try to
identify each of these variables in each of the trial data
sets. During this stage, we will check definitions of vari-
ables in the individual trials and, if necessary, create our
own definitions to ensure commonality of terms
between trials. We will then adapt or recalculate some of
the original variables to ensure consistency of defini-
tions. We will request and extract data about all out-
comes of interest necessary to conduct analyses
following the intention-to-treat (ITT) principle.
All data sets will be worked on separately in order to
standardise variable names and value labels across trials.
Data will initially be entered into an Excel database and
converted to SAS for analysis. Finally, we will collate
data sets and assign a trial variable with a code for each
trial. For each study, relevant descriptive data of all
enrolled patients will be presented, including
demographic data (eg, age and gender), underlying
diagnosis (type of cancer and stage), other baseline
clinical and laboratory data, including defining
criteria for the stage of their disease, other blood
markers of inflammation (eg, D-dimer and P-selectin),
results of diagnostic tests and prognostic scores or
comorbidities.
We will match data after recoding of variables into
common variables. The percentage of missing data in
analyses relevant variables will be calculated and Little’s
method will be used to assess the missing completely at
random (MCAR) assumption in the variable with at least
5% of missing data. In case the MCAR is violated, we will
further examine the MAR pattern by comparing the
outcome in the variable with and without missing values.
Thus, we will extract data on:
Participants
1. Number of patients randomised to each treatment
arm
2. Number of patients followed-up in each treatment
arm
3. Number of patients who withdrew from treatment in
each treatment arm
4. Number of patients who discontinued treatment in
each treatment arm
5. Population characteristics (age, sex, duration,
co-morbidities, and type and stage of cancer,
co-interventions)
6. Inflammatory markers (P-selectin, C reactive protein,
D-dimer)
Interventions
1. Type of parenteral anticoagulant studied
2. Dosage of treatment
3. Duration of treatment
4. Inpatient versus outpatient treatment
Outcomes
1. All-cause mortality; prespecified at 12 months,
24 months and over the duration of the trial
2. Overall and symptomatic venous thromboembolism
(DVT and/or PE): DVT events must be diagnosed
using an objective diagnostic test such as: venography,
or compression ultrasound. PE events have to be
diagnosed using an objective diagnostic test such as:
pulmonary perfusion/ventilation scans, CT, pulmon-
ary angiography or autopsy
3. Health-related quality of life: has to be measured
using a validated tool
4. Major bleeding: we will accept the authors’ defini-
tions of major bleeding
5. Minor bleeding: we will accept the authors’ defini-
tions of minor bleeding
6. Thrombocytopaenia
Data analysis
We plan to use SAS V.9.3 (Cary, North Carolina, USA)
or a newer version of this software to analyse data. All
analyses will follow the ITT principle with all patients
analysed according to the arm to which they were rando-
mised. A consistency check of the raw data from all trials
will be performed. In addition, to ensure that the data
provided correspond to the reported results, we will
reproduce and recalculate the primary outcomes of the
trials and several randomly chosen baseline data.
For the variable that has missing data, we will use a
multiple imputation method to impute the missing data.
We will use the imputed data sets as the main study data-
sets for the statistical analyses. We will summarise the data
in mean or median, depending on the distribution, for
the continuous outcomes (eg, quality of life) together
with SD or IQR. We will use count and percentage to
describe the categorical data. We will express the inter-
vention effects in OR for the dichotomous outcomes, HR
for the time to the event outcomes and mean difference
for the continuous outcomes along with the 95% CIs.
In the regression analyses, we will use multilevel
models32–34 to incorporate the data at trial level and
patient level. For the dichotomous outcomes, we will be
using a logistic mixed model. Since a considerable
number of trials (>10) may be included, we plan to use
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a random-effects model, representing the joint distribu-
tion of the treatment effect and trial with a bivariate
normal distribution (ie, using model (3) from Turner
et al34). Assuming that the trials included in analysis are
a random sample from a larger pool of trials, a
random-effects model may be inappropriate. Therefore,
in addition to random-effects models, fixed-effects
models will also be completed for primary outcomes. A
Cox proportional hazard regression model will be used
for time to event outcomes. The heterogeneity among
the trials will be modelled with frailty random effect. For
the continuous outcomes, we will be using mixed regres-
sion model with random intercept to account the vari-
ability among the trials. The adjusted variables of
comorbidities and age will be included as fixed-effects in
the model. Residuals will be examined to assess the
appropriateness of the model assumptions. We will fit
corresponding models for our prespecified secondary
outcomes. We will also report the anticipated absolute
effects (eg, risk difference or number-needed-to-treat),
based on the estimated OR and HR, and three assumed
baseline risks and median or mean difference in sur-
vival. All data will be summarised in a GRADE evidence
profile.
In addition, we will perform several prespecified sensi-
tivity analyses to investigate differences in pooled effect
estimates related to conduct or methods. We will also
perform subgroup analyses to investigate differences in
pooled effect estimates related to different patient sub-
groups. We will test whether there is a differential inter-
vention effect among the various subgroups with an
interaction-test, which is preferred to separate subgroup
group-specific analyses.35 36
Subgroup analyses will be performed for the following
variables:
1. Underlying diagnosis of included patients (type and
stage of cancer): We hypothesise that patients with
earlier stage cancer have greater benefit than those
with later stage cancer. We also hypothesise, based on
our prior analysis, that patients with lung or pancre-
atic cancer experience a greater benefit from anti-
coagulant therapy.13
2. Concomitant treatment (ie, chemotherapy compared
with no chemotherapy): In patients treated with
chemotherapy we anticipate larger effects of heparin.
Sensitivity analyses:
We have prespecified the following sensitivity analyses:
1. Compare the results of a study-level meta-analysis
including studies for which we will not receive ori-
ginal datasets with the main IPDMA results. We will
then explore if the study-level data differ after exclud-
ing the studies for which we do not receive original
data sets.
2. Higher risk of bias in the original study may be asso-
ciated with a greater effect. We will conduct sensitivity
analysis by comparing results of trials judged at high
risk of bias compared to those judged at low risk of
bias (those that are judged as not suffering from any
of the methodological limitations listed in the risk of
bias assessment above).
For the secondary objective of developing a risk-
prediction model for VTE in patients with cancer we
will perform logistic regression or Cox proportional
hazard regression and competing risk analysis (until
first occurrence of outcome), stratified by cancer type
in patients not receiving therapy, using the studies for
which we will have received IPD sets. The candidate pre-
dictors will be age, gender, cancer stage, chemotherapy,
use of erythropoietin stimulating agents, statin use, the
biochemical markers (P-selectin, C reactive protein and
D-dimer), smoking status, obesity (body mass index),
platelet count, leucocyte count and haemoglobin level
if available (12). The dependent variable will be the
composite of symptomatic lower extremity DVT and PE.
Using manual stepwise backward selection, we will deter-
mine the final model, retaining the predictors with the
strongest statistical effect and those classically consid-
ered risk factors (eg, specific chemotherapies). To
adjust for overfitting, regression coefficients will be
shrinked as needed. The regression coefficients will be
used to calculate individual annual risks and corre-
sponding 95% CIs. Bootstrapping procedures will be
performed for internal validation of the performance
of the new rule.
In parallel, we will perform an external validation of
the Khorana score37 and extended Khorana score,38
using the individual data of patients not receiving
LMWH. We will recalculate individual risk for patients at
baseline (expected, E) using the Korana score and the
extended model including D-dimer and soluble
P-selectin concentration. We will then assess the inci-
dence of VTE (observed, O), for each score on the
Khorana or extended Khorana score. We will perform
net classification analysis and offset regression to verify
the need for recalibration, and proceed to recalibrate if
necessary. We will also dichotomise the Khorana score
and extended Khorana score (cut-off ≥3 points) to
recalculate the sensitivity, specificity, negative predictive
value and positive predictive value on the validation set.
DISCUSSION
This will be the first IPDMA to address the health effects
of heparin on patients with cancer and to provide
important background for decision makers in this field.
Our results will likely receive attention in the next edi-
tions of several guidelines given the participation of
several investigators in guideline development groups
(eg, the American Society of Hematology, Cancer Care
Ontario, American Society of Clinical Oncology and
National Comprehensive Cancer Network). A number of
knowledge users will be directly involved in the project
on various occasions. They will take ownership through
the involvement with all stages of the project and coau-
thoring of the publications resulting from this knowl-
edge synthesis. Our next guidelines will be conducted
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with the American Society of Hematology (ASH) and
the VTE in Cancer has formulated questions to be
answered by this synthesis. We believe that this offers an
outstanding opportunity for dissemination. The guide-
line developers will use the results of this synthesis to
inform their guideline recommendations and practice.
Several of the knowledge users will disseminate the
results through presentations at clinical rounds as well as
national and international conferences. Weaknesses of
our study are in the risk of not obtaining data from all
studies that will be identified. In addition to our exten-
sive search and robust analysis, the strength of our study
relates to the possibility of identifying patient-level effect
modifiers and exploring the survival benefit suggested
by our study-level meta-analysis.
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